anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a medicine for treating lumbar disc herniation and a preparation method thereof. The medicine is prepared by radix angelicae pubescentis, loranthus parasiticus, radix angelicae, ligusticum wallichii, notopterygium roots, caulis piperis futokadsurae, sargentg loryvine, ramulus mori, radix clematidis, pseudo-ginseng, astragalus mongholicus, angelica sinensis, radix paeoniae alba, caulis spatholobi, aalty cortex eucommiae, medicinal cyathula roots, teasel roots, drynaria rhizome, rhizoma cibotii, herba epimedii, golden cypress and pachyrhizua angulatus which are evenly mixed. After being crushed, the mixture is evenly mixed with frankincense and myrrh with the formula amount, and 70%-95% (V/V) ethanol is utilized to perform heating, reflux and extraction for two to three times. Each extraction lasts for one to three hours, filtrate is filtered and merged, the ethanol is recovered, the filtrate is concentrated to thick paste with relative density ranging from 1.05 to 1.35 under 60 DEG C, menthol crystal and borneol are added into the thick paste, and the thick paste is evenly stirred and then prepared into various different preparations. The medicine for treating lumbar disc herniation adopts more than twenty raw material medicines for matching and jointly increasing effects of nourishing liver, tonifying kidneys, removing coldness and damp, promoting qi, activating blood circulation and clearing and activating channels and collaterals, has good curative effects on a lumbar disc herniation disease, and has no side effects. The recurrence rate is extremely low.
Provided is a hemostatic agent for internal body use, which can be applied onto a bleeding lesion of the gastrointestinal tract by an endoscopic hemostatic method, and a method of applying the hemostatic agent onto the bleeding lesion. The coating agent is a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution. The coating agent hemostatic agent for stopping bleeding from a lesion of a mucous membrane by being applied onto the lesion of the mucous membrane through an endoscope, comprising a coating agent as a polymer solution prepared by dissolving a cationic or an anionic reaction product into a polysaccharide solution, wherein the coating agent has adherence high enough to flowthrough an endoscope catheter, biocompatibility, and bioadherence induced by the interaction with mucous membrane due to hydrogen bonds, ion bonds or hydrophobic bonds. According to the hemostatic agent and method thereof, since the hemostatic agent is applied onto an ulcer through an endoscope, the ulcer can be completely covered with the hemostatic agent. As a result, bleeding from the ulcer can be totally stopped and there is no major probability of rebleeding. Further, since the hemostatic agent contains the supplement, the ulcer can be cured by the medical effect and growth factor of the supplement.
BACKGROUND Gestational diabetes mellitus (GDM) affects 5.8-12.9% of pregnant women, while pre-gestational diabetes mellitus (PGDM) affects 0.4-1.1%. GDM increases the risk of perinatal complications and long-term health issues. This retrospective study from a single centre in Rzeszów, Poland aimed to evaluate maternal and neonatal outcomes of pregnancy of 65 women with gestational diabetes mellitus. MATERIAL AND METHODS The study group consisted 65 women with GDM. The control group consisted 60 women without. GDM were diagnosed with carbohydrate metabolism disorders during pregnancy based on the results of the oral glucose tolerance test (OGTT). Methods of evaluation of the mothers: age, body mass before pregnancy, body height, body mass index (BMI), gravidity, parity, the number of miscarriages, length of stay (LOS) of mother, gestational weight gain (GWG), duration of pregnancy, type of delivery, treatment of diabetes. Methods of evaluation of the child: LOS, birth weight, Apgar points. RESULTS Women with diabetes stayed in hospital longer than women without, similarly applies the length of stay (LOS) of the child (p<0.001). It turned out that the women with GDM were significantly more likely to deliver by caesarean section (CS) (p=0.024) and these women most often had gestational weight gain (GWG) within the recommended range (p<0.001). Body mass index (BMI) before pregnancy was significantly higher in the women with GDM (p=0.023). CONCLUSIONS The above study confirms that the occurrence of GDM has an undoubted impact on prolonged LOS of the mother and child, more frequent CS delivery and normal GWG.
Individually titrate APADAZ to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving APADAZ to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [ see Warnings and Precautions (5.1)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. 

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the APADAZ dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

Total dosage of APADAZ and any concomitant acetaminophen-containing products should not exceed 4000 mg of acetaminophen in a 24-hour period.
With the advancement of deep learning technology, computer-aided diagnosis (CAD) is playing an increasing role in the field of medical diagnosis. In particular, the emergence of Transformer-based models has led to a wider application of computer vision technology in the field of medical image processing. In the diagnosis of thyroid diseases, the diagnosis of benign and malignant thyroid nodules based on the TI-RADS classification is greatly influenced by the subjective judgment of ultrasonographers, and at the same time, it also brings an extremely heavy workload to ultrasonographers. To address this, we propose Swin-Residual Transformer (SRT) in this paper, which incorporates residual blocks and triplet loss into Swin Transformer (SwinT). It improves the sensitivity to global and localized features of thyroid nodules and better distinguishes small feature differences. In our exploratory experiments, SRT model achieves an accuracy of 0.8832 with an AUC of 0.8660, outperforming state-of-the-art convolutional neural network (CNN) and Transformer models. Also, ablation experiments have demonstrated the improved performance in the thyroid nodule classification task after introducing residual blocks and triple loss. These results validate the potential of the proposed SRT model to improve the diagnosis of thyroid nodules' ultrasound images. It also provides a feasible guarantee to avoid excessive puncture sampling of thyroid nodules in future clinical diagnosis.
Climacterium is a life period in which women move from the reproductive age to the period when their reproductive ability is lost due to the decrease in ovarian functions. The most common climacteric disorder is vasomotor changes. The most common problem seen in menopausal period after vasomotor complaints is insomnia.

Sleep disorders seen in climacteric period negatively affect the quality of life and psychosocial health of woman. In their study, Jean-Louis et al., expressed that women in menopausal period spent approximately 10% of their daily sleep time by sleeping outside the bed during the day. 61% of menopausal women woke up at least once a week and several times from the night's sleep. In their study, Anttalainen et al., determined that women in postmenopausal period had more sleep problems compared to women in premenopausal period. In addition to physical changes due to hormonal changes in climacterium, mental problems such as nervousness, anxiety and depression developing in women may negatively affect the relationships in family environment especially the communication with the spouse. Besides, it is thought that an incompatible marriage can increase menopausal complaints. In the studies investigating the relationship between menopausal complaints and marital adjustment, women with compatible marital life were found to experience less menopausal complaints. Due to the negative effects of physician-controlled hormone replacement treatment administered to reduce menopausal symptoms, demand for non-pharmacological interventions has increased and women have started to accept that therapeutic massage is safe and contributes to health. It is stated that women experience insomnia, a symptom of menopause, and tend to choose especially body therapies from alternative therapies in the first place. Massage is widely accepted as a treatment tool. Although the menopausal period is physiological, it is a period that must be addressed specifically by healthcare professionals since it is accompanied by pathological events causing distress in life and impairing the quality of life.

The purpose of this study is to determine the effect of back massage applied by partners on menopausal complaints, sleep quality, and marital adjustment of women in climacteric period.
The present invention relates to a medicinal prescription prepared by the application of matching traditional Chinese medicines for treating hepatitis and a product containing the prescription. The medicine is in the form of an oral preparation with the medicinal effect of treating hepatitis, and is prepared by matching the traditional Chinese medicines of epimedium, giant knotweed rhizome, red peony root, dandelion, astragalus root, rhubarb, ganoderma, glossy privet fruit, bushy sophora, glabrous greenbrier rhizome, etc. through extraction and concentration. The ALT normalization rate is 51.6% for chronic persistent hepatitis and 59.4% for chronic active hepatitis. The AST normalization rate is 48.4% for chronic persistent hepatitis and 62.3% for chronic active hepatitis. The inhibiting rate on HBV-DNA and DNA-P is 76.1% and 78.4% respectively. The medicine has the advantage of no toxic or side effect.
Aging is considered a dynamic and progressive process, in which morphological, functional and biochemical changes occur. One of the factors associated with old age is the decrease in the ability to balance posture and the high risk of falls. The literature brings the benefits of physical exercise in improving balance and preventing falls. However, few studies point to the benefits of flexibility techniques and their relationship with balance. The objective of this research is to evaluate the immediate effect of the muscle energy technique (TEM) on postural control responses in the elderly and young adults. The sample will be selected for convenience, with 50 participants of both sexes, young people between 18 and 35 years old and elderly people between 60 and 85 years old. Evaluation of postural control will be performed through the force platform during the unipodal and semi-tandem balance tests (2 repetitions of 30 seconds each, with rest of 30 seconds between them). The main parameters of postural control will be calculated using the pressure center derivative. After the balance tests, the participants will be submitted to TEM and immediately afterwards reassessed on the force platform. An analysis of variance will be used to compare the effects between groups (young versus elderly) and intervention (pre- and post-TEM) and the effects of interaction on the main variables of postural control. A beneficial effect of TEM is expected, especially in the elderly group. The results found in this study will contribute to the use of TEM and the increase of relevant clinical information to benefit the ability to balance in the elderly, in order to reduce the risk of falls.
A hypoxia occurred in eutrophic estuary was predicted using long short-term memory (LSTM) model with prediction time steps (PTSs) of 0, 1, 12, and 24 h. A capacitive potential (CP), which provides quantitative information on dissolved oxygen (DO) concentration, was used as a predictor along with precipitation, tide level, salinity, and water temperature. First, annual changes in DO concentration were clustered in three phases of annual DO trends (oversaturation, depletion, and stable) using k-means clustering. CP was the most influential variable in clustering the DO phases. The LSTM was implemented to predict the DO phases and hypoxia occurrences. In the simultaneous prediction of the depletion phase and hypoxia occurrence with a 12 h PTS, the accuracy was 92.1% using CP along with other variables; it was 3.3% higher than that achieved using variables other than CP. In the case of predicting the depletion phase and hypoxia non-occurrence using CP along with other variables, the accuracy was 61.1%, which was 5.5% higher than that when CP was not used. When using CP along with other variables, the total accuracy was highest for all PTS. Overall, the utilization of CP and machine learning techniques enables accurate predictions of both short-term and long-term hypoxia occurrences, providing us with the opportunity to proactively respond to disasters in aquaculture and environmental management due to hypoxia.
Provided are a sympathetic nerve depressant which depresses the activity of the sympathetic nerve in a more effective manner and a skin temperature reducing agent which reduces the skin temperature. Also provided are a cosmetic composition, foods, and miscellaneous goods which have a sympathetic nerve depressing effect or a skin temperature reducing effect. Since the activity of the sympathetic nerve can be tranquilized by 1,8-cineol, the sympathetic nerve depressant effectively depresses the activity of the sympathetic nerve. Also, as 1,8-cineol reduces the skin temperature of cheeks and finger tips, the skin temperature reducing agent effectively reduces the skin temperature. Additionally, the cosmetic composition, foods, and miscellaneous goods containing the sympathetic nerve depressant or the skin temperature reducing agent comprise 1,8-cineol, it will provide a sympathetic nerve depressing effect or a skin temperature reducing effect. the sympathetic nerve depressant contains 0.00001 to 100 wt% of 1,8-cineol, more preferably, 0.001 to 50wt% of 1,8-cineol.
PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition useful as an immunomodulator, an anti-inflammatory agent, a treating agent for intractable infectious diseases or a formation-inhibiting agent or a disrupting agent of biofilm by compounding the enantiomer of fosfomycin or its salt. SOLUTION: This pharmaceutical composition contains the enantiomer of fosfomycin or its salt. The enantiomer of fosfomycin is preferably used in a form of a salt. For example, the sodium salt or the calcium salt is cited as the salt of fosfomycin. When used as a treating agent for an intractable infectious disease, the enantiomer of fosfomycin or its salt is preferably compounded with an antibacterial agent in an amount of 0.5-2mol based on 1mol of the enantiomer or its salt. As the antibacterial agent, e.g. gentamycin or a β-lactam agent is cited. A daily dose of the enantiomer of fosfomycin is preferably 0.2-1g/ adult in the case where it is used as an immunomodulator, an anti-inflammatory agent or a biofilm-formation inhibiting agent, and the medicine is preferably administered in one or several divided doses.
Androgens can modulate immune cell function and may contribute to differences in the prevalence and severity of common inflammatory conditions. Although most immune cells are androgen targets, our understanding of how changes in androgen bioavailability can affect immune responses is incomplete. Androgens alter immune cell composition, phenotype, and activation by modulating the expression and secretion of inflammatory mediators or by altering the development and maturation of immune cell precursors. Androgens are generally associated with having suppressive effects on the immune system, but their impacts are cell and tissue context-dependent and can be highly nuanced even within immune cell subsets. In response to androgens, innate immune cells such as neutrophils, monocytes, and macrophages increase the production of the anti-inflammatory cytokine IL-10 and decrease nitric oxide production. Androgens promote the differentiation of T cell subsets and reduce the production of inflammatory mediators, such as IFNG, IL-4 and IL-5. Additionally, androgens/androgen receptor can promote the maturation of B cells. Thus, androgens can be considered as immunomodulatory agents, but further work is required to understand the precise molecular pathways that are regulated at the intersection between endocrine and inflammatory signals. This narrative review focusses on summarising our current understanding of how androgens can alter immune cell function and how this might affect inflammatory responses in health and disease.
PURPOSE:To provide a blood coagulation promoting agent or hemostatic agent, containing a compound having lignan skeleton and having oxygen-containing chain or oxygen-containing ring on the side chain as an active component, effective to shorten the blood coagulation time, and enabling the separation of serum quickly in high yield in a serum test, etc. CONSTITUTION:The objective blood coagulation promoting agent or hemostatic agent can be produced by using one or more kinds of the compounds having lignan skeleton and having oxygen-containing chain or oxygen-containing ring on the side chain, e.g. l-sesamin, l-asarinin, paulownin, sesamolin, etc., as active components. The amount of the active component is preferably 0.1-20mg per 1ml of blood. It shortens the blood coagulation time, promotes the clot retraction, leaves no fibrin in the serum, is almost free from hemolytic property and is usable for various tests without affecting the measured value of the test items. Serum test and blood coagulation test can be carried out in a short time in high efficiency by the use of the present agent.
Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, "Detailed Description" for additional treatment information.
Copper is an essential element in the diet of mammals, including humans. It plays an important role in the physiological regulation of various enzymes and is consequently involved in several biological processes such as angiogenesis, oxidative stress regulation, neuromodulation, and erythropoiesis. Copper is essential for facilitating the transfer of iron from cells to the bloodstream, which is necessary for proper absorption of dietary iron and the distribution of iron throughout the body. In particular, patients with end-stage renal failure who require renal replacement therapy are at increased risk for disorders of copper metabolism. Many studies on hemodialysis, peritoneal dialysis, and kidney transplant patients have focused on serum copper levels. Some reported mild deficiency, while others reported elevated levels or even toxicity. In some cases, it has been reported that alterations in copper metabolism lead to an increased risk of cardiovascular disease, malnutrition, anemia, or mielopathy. The aim of this review is to evaluate the role of copper in patients undergoing hemodialysis and its potential clinical implications.
Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).
Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition.
At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed using direct laparscopic visualization with the Carter-Thomason fascial closure device with a single interrupted suture of 0-vicryl.
In a multicenter, double-blind, placebo-controlled setting, participants are randomly allocated to either a smokefree, oral tobacco product or a non-tobacco, non-nicotine placebo product with identical flavoring and physical appearance. The study consists of three phases: Study Product Test Period (4 weeks), Intervention Phase (12 weeks), and a Follow-Up Phase (12 weeks). The participants are all cigarette smokers who are motivated to quit. They are encouraged to gradually substitute as many cigarettes as possible with study products during the Study Product Test Period and to refrain from all cigarettes at the latest by the first day of Week 5. Use of study products will continue during the 12 week Intervention Phase. The participants are encouraged to cut down on use of study products during the last 3 weeks to avoid a too abrupt ending of nicotine intake.

All subjects are encouraged to continue in the study for clinical follow-up independent of smoking status although use of study products is discontinued during the Follow-Up Phase. If a subject has managed to quit smoking during the Intervention Phase but there is an imminent danger of smoking relapse during the Follow-Up Phase, that subject is informed that use of nicotine replacement therapy or a smokefree tobacco product is a better option in terms of health risks than a smoking relapse.
Cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day given over 3 days by IV infusion followed by a single dose of 1-3x10\^7 huCART-meso cells/m\^2 via intraperitoneal (i.p.) administration. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells.
This study is a prospective cross-sectional research. A total of 52 healthy individuals participated in this study. The test protocols were compeleted in two sessions for each participant. In the first session, participants whose eligibility for the study was determined, were recorded demographic data including age, height, body weight, body mass index, lower extremity dominance, and leg length. Subsequently, the Lower Quarter Y Balance Test (LQYBT) was conducted using three different focus instructions: (1) standardized instruction, (2) internal focus instruction, (3) external focus instruction. Each focus instruction was sequentially applied three times in each direction. The three different instructions were randomized and performed in a different sequence for each participant. In second session, to assess the test-retest reliability of different focus instructions during test, the LQYBT was repeated under the same conditions three days later, by the same researcher.

To ensure normalization, the average distances measured in the anterior, posteromedial, and posterolateral directions were obtained for each command, and the results were divided by the length of the leg and multiplied by 100. The total score for the dominant side in the LQYBT was determined by aggregating the average reach distance across three directions, dividing it by three times the length of the leg, and then multiplying by 100.